Newly diagnosed patients with AL amyloidosis who harbor t(11;14) see less treatment benefit with bortezomib, according to a recent study published in the Journal of Clinical Oncology.

Researchers led by Tilmann Bochtler, MD, of the University Hospital Heidelberg in Germany examined 101 patients with AL amyloidosis who were treated with bortezomib-dexamethasone as first-line treatment through interphase fluorescence in situ hybridization (iFISH).

“Bortezomib has become a cornerstone in the treatment of AL amyloidosis,” the authors noted. “We addressed the prognostic impact of cytogenetic aberrations for bortezomib-treated patients.”

Continue Reading

They found that there was inferior hematologic event-free survival, overall survival, and remission rate in patients who had t(11;14) compared to those who didn’t.

RELATED: Diagnosis and Management of Castleman Disease

In multivariable Cox regression models, t(11;14) was found to be an independent adverse prognostic marker for hematologic event-free and overall survival, but not remission.

“iFISH results are important independent prognostic factors in AL amyloidosis,” the authors concluded.


  1. Bochtler, Tilmann, et al. “Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens.” Journal of Clinical Oncology. doi: 10.1200/JCO.2014.57.4947. [epub ahead of print]. March 16, 2015.